Tolerance and Pharmacokinetics of TQB2450

CTTQ

Status and phase

Unknown

Phase 1

Conditions

Tumor

Treatments

Drug: TQB2450

Study type

Interventional

Funder types

Industry

Identifiers

NCT03460457

TQB2450-I-01

Details and patient eligibility

About

To study the pharmacokinetic characteristics of TQB2450 in the human body, recommend a reasonable regimen for subsequent research.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with advanced malignancy diagnosed with pathology or cytology who have failed standard treatment or no standard treatment;
18-70 years old;Eastern Cooperative Oncology Group performance status:0-1,Life expectancy of more than 3 months;
Main organs function is normal;
Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped;
Patients should be voluntary and sign the informed consents before taking part in the study;

Exclusion criteria

Patients who have received programmed cell death protein 1(PD-1) or programmed cell death protein ligand(PD-L1) antibody treatment;
Patients who had any> 3 degree immune-related adverse event during any previous immunotherapy received;
Appeared severe hypersensitivity after taking other monoclonal antibody drugs;
Other malignancies have been diagnosed in the past 2 years except cured or locally curable cancers, such as cutaneous or squamous cell carcinoma, superficial bladder cancer, cervical cancer or orthotopic carcinoma of the breast;
Known spinal cord compression, cancer meningitis patients, new onset of central nervous system metastasis or stable control of symptoms in patients with brain metastases less than 4 weeks; asymptomatic and stable imaging without the need for corticosteroid treatment；
Patients with hypothyroidism over 2 degrees;
Patients with active, or who have had, and are likely to relapse, autoimmune diseases; the following patients are enrolled: skin disorders without systemic treatment (eg vitiligo, psoriasis, hair loss);
Patients treated with glucocorticoids or other immunosuppressive agents within 4 weeks prior to dosing;
Interstitial lung disease or non-contagious pneumonia (including past history and current illness); uncontrolled systemic diseases including diabetes, hypertension, pulmonary fibrosis, acute lung disease, etc. except for radiotherapy-induced interstitial pneumonitis;
Serious chronic or active infections require systemic antibacterial, antifungal or antiviral treatment (allowing antiviral treatment in patients with hepatocellular carcinoma), including tuberculosis infection;
Unstable pleural effusion, pericardial effusion or ascites;
Significant cardiovascular diseases such as heart failure of New York Heart Academy(NYHA) Class 2 and above, myocardial infarction within the past 3 months, unstable arrhythmias (including QT interval ≥480 ms) or unstable Angina;
Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history;
Hypertension (systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication;
Hepatitis B virus patients with active replication (DNA> 500 cps / mL), hepatitis C;
The first medication interval from the patient: the last chemotherapy for at least 4 weeks, biological products at least five half-lives;
The first medication interval from the patient: the last chemotherapy for at least 4 weeks, biological products at least five half-lives;
Inoculated with vaccine or attenuated vaccine within 4 weeks before first administration;
Major surgery, or unhealed wounds, ulcers or fractures within 4 weeks prior to the first dose;